Comparison of Tofacitinib and Ustekinumab as Third-Line Therapy in Relapsed UC
In patients who do not respond to conventional treatments, biotherapies with anti-TNF and anti-integrin (vedolizumab) are the treatments of choice in 1re line for moderate to severe illness. However, a non-negligible percentage of these patients do not respond or subsequently escape these treatments. The recent availability of ustekinumab (anti-IL12/23) and tofacitinib (anti-JAK) in these refractory … Read more